Activated Prothrombin Complex Concentrate Versus 4-Factor Prothrombin Complex Concentrate for Vitamin K-Antagonist...

Area of Science:

• Hematology
• Pharmacology
• Clinical Medicine

Background:

• Warfarin is a widely used anticoagulant, but its use is associated with a risk of hemorrhage.
• Prothrombin complex concentrates (PCCs) are used to rapidly reverse warfarin's effects.
• There are different formulations of PCCs, including activated and 4-factor PCCs, with varying efficacy and safety profiles.

Purpose of the Study:

• To compare the international normalized ratio (INR) normalization efficacy of activated prothrombin complex concentrate (aPCC) and 4-factor prothrombin complex concentrate (4F-PCC).
• To evaluate the incidence of thrombotic complications in patients treated with aPCC or 4F-PCC for warfarin-associated hemorrhage.

Main Methods:

• Retrospective, multicenter cohort study.
• Included patients >18 years old treated for warfarin-associated hemorrhage with aPCC or 4F-PCC.
• Excluded patients receiving PCC for other indications, pregnant patients, those with baseline INR < 2, massive transfusion, or plasma treatment.

Main Results:

• 158 patients analyzed (118 aPCC, 40 4F-PCC).
• Both aPCC and 4F-PCC achieved similar posttreatment INR levels.
• aPCC showed higher odds of achieving INR < 1.2 (OR, 3.23; P = 0.0088).
• Only one thrombotic complication was reported posttreatment.

Conclusions:

• A low, fixed dose of aPCC is as effective as standard dose 4F-PCC for INR normalization in warfarin-associated hemorrhage.
• No increased risk of thrombotic events was observed with either PCC formulation.